Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering
December 20, 2024
INmune Bio, Inc. Announces Submission of Investigational New Drug (IND) Application for INKmune(TM) to the U.S. Food and Drug Administration for Treatment of Metastatic Castration-Resistant Prostate Cancer
April 3, 2023
Related Post
-
-
Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)
December 20, 2024
-
INOVIO Announces Pricing of $30 Million Public Offering
December 13, 2024
-
Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures’ Acquisition of Lumos Pharma
December 12, 2024